文献速递颈动脉与弓上血管

颈动脉内膜剥脱术与支架术的无症状状态持续时间及结局:CREST 试验分析

Duration of asymptomatic status and outcomes following carotid endarterectomy and carotid artery stenting in the Carotid Revascularization Endarterectomy vs Stenting Trial.
PubMed 文献 · J Vasc Surg · 2019-01-08

在 CREST 试验的 1181 例无症状患者中,1104 例(93%)为一直无症状(AA),77 例(7%)为既往有症状但当前无症状(PS)。围术期卒中/死亡、4 年卒中/死亡及 4 年主要终点在 AA 与 PS 组间均无差异,CEA 和 CAS 分别分析亦无差异。

要点

  • 无症状患者中仅少数(7%)有同侧既往症状,当前无症状但既往有症状者与一直无症状者结局无差异。
  • 围术期卒中/死亡、4 年卒中/死亡及 4 年主要终点在 AA 与 PS 组间均无统计学差异。
  • CEA 和 CAS 分别分析时,AA 与 PS 组间上述结局同样无差异。

核心结论

  • 在 CREST 试验中,无症状患者仅少数有同侧既往症状,AA 与 PS 患者的围术期及 4 年结局无差异。

研究设计与样本

  • CREST 随机试验中无症状患者的回顾性比较分析,共 1181 例,AA 1104 例(93%),PS 77 例(7%)。
  • 患者随机接受颈动脉内膜剥脱术(CEA)或颈动脉支架置入/血管成形术(CAS),采用校正年龄、性别和治疗的风险比例模型分析。

主要发现

  • pooled CAS+CEA 人群中,AA 与 PS 的围术期卒中/死亡分别为 2.0% vs 1.3%,4 年卒中/死亡 3.6% vs 3.2%,主要终点 5.2% vs 5.8%,均无差异。
  • CEA 组中,AA 与 PS 的围术期卒中/死亡 1.5% vs 0%,4 年卒中/死亡 2.7% vs 0%,主要终点 5.1% vs 2.4%。
  • CAS 组中,AA 与 PS 的围术期卒中/死亡 2.5% vs 2.8%,4 年卒中/死亡 4.4% vs 6.9%,主要终点 5.3% vs 9.8%。

临床怎么用

  • 对于当前无症状但既往有同侧症状的患者,血运重建(CEA 或 CAS)的围术期及 4 年风险与一直无症状者相似,可参考相同决策框架。

局限性

  • PS 组样本量小(77 例),可能不足以检测组间微小差异。
  • 分析为 CREST 试验的事后比较,非预设主要分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most carotid revascularization studies define asymptomatic as symptom-free for more than 180 days; however, it is unknown if intervention carries similar risk among those currently asymptomatic but with previous symptoms (PS) vs those who were always asymptomatic (AA). METHODS: We compared the periprocedural and 4-year risks of PS vs AA patients in the Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) randomized to carotid endarterectomy (CEA) or carotid artery stenting (CAS)/angioplasty. Proportional hazards models adjusting for age, sex, and treatment were used to assess the risk of periprocedural stroke and/or death (S+D; any S+D during periprocedural period), stroke and death at 4 years (any S+D within the periprocedural period and ipsilateral stroke out to 4 years) and the primary end point at 4 years (any stroke, death, and myocardial infarction within the periprocedural period and ipsilateral stroke out to 4 years). Analysis was performed pooling the CEA-treated and CAS-treated patients, and separately for each treatment. RESULTS: Of 1181 asymptomatic patients randomized in CREST, 1104 (93%) were AA and 77 (7%) were PS. There was no difference in risk when comparing the AA and PS cohorts in the pooled CAS+CEA population for periprocedural S+D (2.0% vs 1.3%), S+D at 4 years (3.6% vs 3.2%), or the primary end point (5.2% vs 5.8%). There were also no differences among those assigned to CEA (periprocedural S+D, 1.5% vs 0%; S+D at 4 years, 2.7% vs 0%; or primary end point, 5.1% vs 2.4%) or CAS (periprocedural S+D, 2.5% vs 2.8%; S+D at 4 years, 4.4% vs 6.9%; or primary end point, 5.3% vs 9.8%) when analyzed separately. CONCLUSIONS: In CREST, only a small minority of asymptomatic patients had previous ipsilateral symptoms. The outcomes of periprocedural S+D, periprocedural S+D, and ipsilateral stroke up to 4 years, and the primary end point did not differ for AA patients compared with PS patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Moore WS, Voeks JH, Roubin GS, et al. Duration of asymptomatic status and outcomes following carotid endarterectomy and carotid artery stenting in the Carotid Revascularization Endarterectomy vs Stenting Trial. J Vasc Surg. 2019. PMID: 30630649. doi:10.1016/j.jvs.2018.09.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。